Fig. 2
The disruption of SHP-1 enhanced the cytolysis of CAR T cells in vivo. (A) Schematic diagram of CAR-T cell therapeutic mouse model construction. 1 × 106 target cells (U251-CD133-luc) were seeded subcutaneously on the back of NPG mice. 2 × 106 CAR T cells infusion therapy was performed on Day1, Day8, Day11, and Day18, respectively, and imaging tracking of tumor sizes were performed every 2–3 days. (B) Tumor size were detected by using in vivo imaging systems during CAR T cell treatment. The time point of the first T cell therapy was recorded as Day1, and the tumor growth in mice was recorded on Day1, Day8, Day11, and Day18, respectively. (C) Body weight were measured in mice treated with CD133 CAR T cell and SHP-1 KO CD133 CAR T cells. (D) Tumor size were evaluated by quantified the areas of luciferase signal. Each curve represents the luminescence signal value of tumor in one mouse. (E) The mean value of luminescence signal of tumors in mice treated with CD133 CAR T cells and SHP-1 KO CD133 CAR T cells were evaluated. **P < 0.01 indicates a significant difference between the different time points (n = 6, one-way ANOVA in C). *P < 0.05 or **P < 0.01 indicates a significant difference between CD133 CAR T cells and SHP-1 KO CD133 CAR T cells (n = 6, one-way ANOVA in E, and Tukey posttest). ns, not significant